Cure8 research brief
The findings highlight that older adults are less likely to be prescribed advanced IBD therapies, which could reflect prescribing patterns, comorbidities, insurance factors, or access issues relevant to treatment planning and equity discussions.
Clinicians, health systems/policymakers focused on access and equity, researchers studying IBD treatment disparities, and adult IBD patients (particularly those considering or using biologics/immunomodulators).
Researchers examined records for >60,000 people with Crohn's disease or ulcerative colitis in Epic Cosmos and measured prior exposure to advanced therapies. Overall exposure to advanced therapies was reported for 43.6% of patients during the study window.
Multivariable analyses showed patients older than 25 were less likely to receive several classes of advanced medications; Medicare coverage was also associated with lower odds of receiving some drugs.
This is a large retrospective EHR-based study reporting associations from 2015–2024; it does not establish causality and may be influenced by coding, prescription capture, and unmeasured clinical factors.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Patients and clinics are still deciding how much care can be done remotely. Knowing who prefers in-person versus remote visits helps tailor care so patients receive the visit type they need and want, and supports...
This study quantifies the large NHS and societal costs of Crohn’s disease and ulcerative colitis in the UK and highlights that ongoing management and maintaining remission are major drivers of expense.
If biologic availability, infusion capacity, or therapeutic drug monitoring are limited where you live, oral JAK inhibitors could offer a practical, effective alternative for moderate‑to‑severe IBD, according to this...
